menu
    • menu

    Company profile for Inotrem

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Inotrem is a biotechnology company specialized in immunotherapy for acute inflammatory syndromes, such as septic shock. Founded in 2013, with offices in Paris and a technology center in Nancy (France), the company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Leveraging its proprietary technology platform, Inotrem has developed the first-in-class...
    Inotrem is a biotechnology company specialized in immunotherapy for acute inflammatory syndromes, such as septic shock. Founded in 2013, with offices in Paris and a technology center in Nancy (France), the company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Leveraging its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, nangibotide (LR12), with applications in a number of therapeutic indications such as septic shock or myocardial infarction.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    InotremFrance Flag
    Country
    Country
    France
    Address
    Address
    114 rue la Boétie 75008 Paris
    Telephone
    Telephone
    +33 9 66 81 79 00
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.inotrem.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Inotrem Reveals Nangibotide Clinical Strategy for Septic Shock
    Inotrem Reveals Nangibotide Clinical Strategy for Septic Shock

    23 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/23/3120247/0/en/Inotrem-Unveils-Game-Changing-Precision-Medicine-Strategy-for-Nangibotide-Clinical-Development-in-Septic-Shock.html

    GLOBENEWSWIRE
    23 Jul 2025
    Share Share
    Inotrem Reaches Agreement with the FDA for a Phase 3 Trial for Nangibotide
    Inotrem Reaches Agreement with the FDA for a Phase 3 Trial for Nangibotide

    08 Jan 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240108252863/en

    BUSINESSWIRE
    08 Jan 2024
    Share Share
    Inotrem Receives Funding From the Crohn’s & Colitis Foundation Ventures Program
    Inotrem Receives Funding From the Crohn’s & Colitis Foundation Ventures Program

    06 Nov 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231105857395/en

    BUSINESSWIRE
    06 Nov 2023
    Share Share
    Inotrem Announces Publication of Two Key Articles on Nangibotide PII Programs
    Inotrem Announces Publication of Two Key Articles on Nangibotide PII Programs

    01 Jun 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230531005754/en

    BUSINESSWIRE
    01 Jun 2023
    Share Share
    Inotrem Receives Funding From the Crohn’s & Colitis Foundation for IBD
    Inotrem Receives Funding From the Crohn’s & Colitis Foundation for IBD

    09 Jan 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230109005241/en

    BUSINESSWIRE
    09 Jan 2023
    Share Share
    Inotrem Announces That the PII Study for Treatment of COVID-19 Meets Endpoints
    Inotrem Announces That the PII Study for Treatment of COVID-19 Meets Endpoints

    25 Oct 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221024005568/en

    BUSINESSWIRE
    25 Oct 2022
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search